Announced Thu, 1 Oct, 2026 · 15:51 IST
Gland Pharma invests USD 21 million in US unit, JV with Fosun arm
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+4.9%1-day move
₹2866.00
prior close
₹2890.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.6+0.7+0.6+0.5+4.9+10.0+6.8———————
Up moveDown movePending
AI summary
Gland Pharma board approved USD 21 million investment in wholly-owned US unit Gland Pharma USA Inc., which will subscribe to 60 percent of newly-incorporated Novelstar Pharma Inc. Fosun Pharma USA Inc. will own the remaining 40 percent, forming a strategic US JV. Novelstar will be a step-down subsidiary of Gland Pharma. Completion is targeted by October 31, 2026. Separately, Director Wenjie Zhang resigned due to pre-occupations and was replaced by Fosun Pharma President Xingli Wang as Non-Executive Director.
Likely market impact
Strategic US expansion via JV with promoter arm; Fosun-linked board change signals tighter group coordination.